Workman P - Search Results

1

Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors.

Smith NF, Hayes A, James K, Nutley BP, McDonald E, Henley A, Dymock B, Drysdale MJ, Raynaud FI, Workman P. Smith NF, et al. Among authors: workman p. Mol Cancer Ther. 2006 Jun;5(6):1628-37. doi: 10.1158/1535-7163.MCT-06-0041. Mol Cancer Ther. 2006. PMID: 16818523

2

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Hostein I, et al. Among authors: workman p. Cancer Res. 2001 May 15;61(10):4003-9. Cancer Res. 2001. PMID: 11358818

3

Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol.

Smith V, Raynaud F, Workman P, Kelland LR. Smith V, et al. Among authors: workman p. Mol Pharmacol. 2001 Nov;60(5):885-93. doi: 10.1124/mol.60.5.885. Mol Pharmacol. 2001. PMID: 11641415

4

HSP90 as a new therapeutic target for cancer therapy: the story unfolds.

Maloney A, Workman P. Maloney A, et al. Among authors: workman p. Expert Opin Biol Ther. 2002 Jan;2(1):3-24. doi: 10.1517/14712598.2.1.3. Expert Opin Biol Ther. 2002. PMID: 11772336 Review.

5

Finding the needle in the haystack: why high-throughput screening is good for your health.

Aherne GW, McDonald E, Workman P. Aherne GW, et al. Among authors: workman p. Breast Cancer Res. 2002;4(4):148-54. doi: 10.1186/bcr440. Epub 2002 Jun 10. Breast Cancer Res. 2002. PMID: 12100740 Free PMC article.

6

Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy.

Seddon BM, Maxwell RJ, Honess DJ, Grimshaw R, Raynaud F, Tozer GM, Workman P. Seddon BM, et al. Among authors: workman p. Clin Cancer Res. 2002 Jul;8(7):2323-35. Clin Cancer Res. 2002. PMID: 12114437

7

Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides.

Ross PJ, George M, Cunningham D, DiStefano F, Andreyev HJ, Workman P, Clarke PA. Ross PJ, et al. Among authors: workman p. Mol Cancer Ther. 2001 Nov;1(1):29-41. Mol Cancer Ther. 2001. PMID: 12467236

8

Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.

Workman P. Workman P. Cancer Detect Prev. 2002;26(6):405-10. doi: 10.1016/s0361-090x(02)00126-5. Cancer Detect Prev. 2002. PMID: 12507224 Review.

9

Validation of liquid chromatography assay for the quantitation of (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid (SU006668) in human plasma and its application to a phase I clinical trial.

Asad Y, Cropp G, Adams A, O'Donnell A, Raynaud F, Judson I, Workman P. Asad Y, et al. Among authors: workman p. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Feb 25;785(1):175-86. doi: 10.1016/s1570-0232(02)00912-1. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 12535850 Clinical Trial.

10

Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.

Workman P. Workman P. Mol Cancer Ther. 2003 Feb;2(2):131-8. Mol Cancer Ther. 2003. PMID: 12589030 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

605 results

Search Page

Filters